2 assets in Scrotum Squamous Cell Carcinoma

Therapeutic assets addressing Scrotum Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Scrotum Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Scrotum Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)